Patents Assigned to Lonza, Ltd.
-
Patent number: 11519515Abstract: A rupture disk includes a body including an internal wall extending from a first end of the body to a second end of the body. The internal wall defines an opening extending through the body. In some embodiments, the body further includes an internal flange formed on the internal wall, and the internal flange has a stepped surface. A rupture membrane is positioned within the body, and secured, for example, by cold welding. The rupture membrane may be secured to the stepped surface. The rupture membrane is positioned within the body such that the rupture membrane does not extend beyond the first end of the body. A process system including the rupture disk is also provided. A method of maintaining a process system that includes the rupture disk is also provided.Type: GrantFiled: September 3, 2019Date of Patent: December 6, 2022Assignee: LONZA LTDInventor: Michael Mietzner
-
Patent number: 11479798Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.Type: GrantFiled: March 28, 2018Date of Patent: October 25, 2022Assignees: BOEHRINGER INGELHEIM RCV GMBH & CO KG, SANDOZ AG, VALIDOGEN GMBH, BIOMIN HOLDING GMBH, LONZA LTD.Inventors: Karlheinz Grillitsch, Guenther Daum, Andreas Grutsch
-
Patent number: 11434474Abstract: The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.Type: GrantFiled: March 13, 2020Date of Patent: September 6, 2022Assignee: LONZA LTDInventors: James Budge, Christopher Mark Smales, Tanya Jeane Knight, Robert Young
-
Publication number: 20220268792Abstract: Disclosed herein are, inter alia, methods and compositions useful for detecting and/or quantifying host cell proteins during the production of a product, e.g., a recombinant protein, e.g., an antibody.Type: ApplicationFiled: May 3, 2022Publication date: August 25, 2022Applicant: LONZA LTD.Inventor: Guojie MAO
-
Publication number: 20220268791Abstract: Disclosed herein are, inter alia, methods and compositions useful for detecting and/or quantifying host cell proteins during the production of a product, e.g., a recombinant protein, e.g., an antibody.Type: ApplicationFiled: May 3, 2022Publication date: August 25, 2022Applicant: LONZA LTD.Inventor: Guojie MAO
-
Patent number: 11401523Abstract: A method of producing a protein of interest (POI) by culturing a recombinant eukaryotic cell line comprising an expression construct comprising a regulatable promoter and a nucleic acid molecule encoding a POI under the transcriptional control of said promoter, comprising the steps a) cultivating the cell line with a basal carbon source repressing the promoter, b) cultivating the cell line with a limited amount of a supplemental carbon source de-repressing the promoter to induce production of the POI at a transcription rate of at least 15% as compared to the native pGAP promoter, and c) producing and recovering the POI; and further an isolated regulatable promoter and a respective expression system.Type: GrantFiled: March 5, 2019Date of Patent: August 2, 2022Assignee: LONZA LTDInventors: Diethard Mattanovich, Brigitte Gasser, Michael Maurer, Roland Prielhofer, Joachim Klein, Jana Wenger
-
Publication number: 20220228954Abstract: A sampling system can include a cassette assembly coupled to a station base that has a plurality of actuators. The cassette assembly can include a cassette base, a cassette top, and an elastomer membrane disposed between the cassette base and cassette top. The cassette base can include a sample inlet, a reservoir for receiving a sample from the sample inlet, a sample outlet, and a fluid flow path extending between the sample inlet, the reservoir, and the sample outlet.Type: ApplicationFiled: April 27, 2020Publication date: July 21, 2022Applicant: Lonza Ltd.Inventors: David Dixon Newbold, David Andrew Hansen, Clinton Boyd Pepper
-
Patent number: 11389599Abstract: The present invention relates to a displacement device, DD, for providing a displacement of a syringe closure system for a syringe relative to the syringe, a testing device, TD, and a method for leakage testing of a connection of a syringe closure system for a syringe with the syringe.Type: GrantFiled: February 7, 2020Date of Patent: July 19, 2022Assignee: Lonza LtdInventors: Martin Vogt, Roman Mathaes, Sarah Pelaez, Anja Matter, Atanas Koulov, Hanns-Christian Mahler
-
Patent number: 11377865Abstract: A campus for fabricating at least one pharmaceutical product has one or more customizable facilities each configured to manufacture the at least one pharmaceutical product, a media/buffer plant, and a utility building connected by a utility line to the media/buffer plant and/or the one or more customizable facilities to provide at least one first utility to the media/buffer plant and/or the one or more customizable facilities via the utility line.Type: GrantFiled: May 26, 2020Date of Patent: July 5, 2022Assignee: LONZA LTDInventors: Leander Biffiger, Sandra Carbonneau, Andre Collioud, Jonathan Fortin, Dominik Imbolden, Torsten Schmidt, Stefan Stoffel, Diego Studer, Christoph Vogel, Stefan Widmer, Tristan Wilkins, Lesley Wood, Alexander Zahiri
-
Patent number: 11377677Abstract: A method for producing a recombinant protein of interest (POI) is provided, comprising the steps of (a) culturing cells in a cell culture medium to express said POI by adding a feed comprising at least one substrate to said cell culture, (b) applying a feeding strategy based on calculating, setting and optionally controlling the specific substrate uptake rate qs of the cells during the induction phase and/or production phase of the POI, wherein qs is set to be close to the maintenance rate of the cell culture; and (c) isolating said POI from the cell culture.Type: GrantFiled: March 2, 2017Date of Patent: July 5, 2022Assignee: LONZA LTDInventors: Wieland Reichelt, Christoph Herwig, Julian Kager, Patrick Sagmeister, Matthias Funke
-
Patent number: 11371002Abstract: A single-use bioreactor is provided. The single-use bioreactor may include a bioprocess container, a shell, at least one agitator, at least one sparger, at least one gas filter inlet port for the sparger(s) and headspace overlay, at least one fill port, at least one harvest port, at least one sample port, and at least one probe. In examples, at least one controller may monitor and control one or more parameters associated with the single-use bioreactor A method to cultivate and propagate mammalian cells is also provided. The method may include cultivating under suitable conditions and in a suitable culture medium in a first single-use bioreactor, transferring the medium containing the cells obtained by propagation from the at least one mammalian cell is into a second single-use bioreactor, transferring the medium containing the cells obtained by propagation from the at least one mammalian cell is into a third single-use bioreactor, and cultivating the cells in the third bioreactor.Type: GrantFiled: September 14, 2020Date of Patent: June 28, 2022Assignee: Lonza LtdInventors: Colin Mark Jaques, Mohsan Waseem Khan, Rita D'Ornelas P. De Barros Costa, Anthony Beaney, David Valentine
-
Patent number: 11359223Abstract: An isolated nucleic acid encoding a leader, which has a specific sequence, an isolated leader peptide encoded by such nucleic acid, an expression cassette comprising such nucleic acid encoding a leader operably linked to a nucleic acid sequence encoding a POI a recombinant yeast host cell or a vector comprising such expression cassette, a method of producing a POI in such yeast host cell, and further the use of the specific nucleic acid for the secretion of a POT from a host cell and/or to increase the secretion of a POT from a host cell.Type: GrantFiled: January 2, 2018Date of Patent: June 14, 2022Assignee: LONZA LTDInventors: Brigitte Gasser, Diethard Mattanovich, Silvia Heiss
-
Patent number: 11353468Abstract: Disclosed herein are, inter alia, methods and compositions useful for detecting and/or quantifying host cell proteins during the production of a product, e.g., a recombinant protein, e.g., an antibody.Type: GrantFiled: April 12, 2017Date of Patent: June 7, 2022Assignee: Lonza Ltd.Inventor: Guojie Mao
-
Patent number: 11346742Abstract: The invention concerns the field of container closure integrity (CCI) and the testing of CCI and relates to a device and a method for leakage testing of a connection between a rubber stopper and a corresponding drug container which can be used for storing drugs under sterile conditions and which is closed by said rubber stopper.Type: GrantFiled: November 22, 2019Date of Patent: May 31, 2022Assignee: Lonza LtdInventors: Martin Vogt, Roman Mathaes, Hanns-Christian Mahler, Atanas Koulov, Gabriele Roidl, Franziska Riesen Fuchs
-
Patent number: 11320422Abstract: Disclosed herein are methods and compositions useful for evaluating, selecting, identifying, or making a cell or cell line that has improved production capacity for generating higher yields of products and/or improved capacity to produce higher quality products. Products, as described herein, can include a polypeptide that is endogenously expressed by the cell, a recombinant polypeptide that is not endogenously expressed, or a non-naturally occurring recombinant polypeptide. The methods described herein include modulating, e.g., inhibiting, the protein degradation pathway by using a proteasome inhibitor, an ER-associated degradation (ERAD) inhibitor, or a ubiquitin pathway inhibitor.Type: GrantFiled: January 6, 2017Date of Patent: May 3, 2022Assignee: Lonza Ltd.Inventors: Colin Mark Jaques, Christopher Mark Smales, Tanya Jeane Knight
-
Patent number: 11236520Abstract: A customizable facility for manufacturing at least one product has at least one modular unit in communication with at least one central unit configured to provide utilities to the at least one modular unit. In some embodiments, the central unit(s) and modular unit(s) are positioned at least partially within a shell. Each modular unit can be a fermentation unit, a pre-viral unit, a post-viral unit, a utility space, a warehouse, a media buffer facility, an office, a personnel unit, or another unit. The modular units can be arranged to maximize a number of modular units within the shell while minimizing a footprint of the shell. A method of assembling a facility for manufacturing at least one product includes providing at least one central unit and providing at least one modular unit in communication with the central unit(s) such that utilities are provided by the central unit(s) to the modular unit(s).Type: GrantFiled: March 10, 2017Date of Patent: February 1, 2022Assignee: LONZA LTDInventors: Jonathan Fortin, Lesley Wood, Stefan Widmer, Sandra Carbonneau, Alexander Zahiri
-
Patent number: 11174236Abstract: The invention discloses a method for preparation of 1,4-sorbitan by dehydration of D-sorbitol, wherein one equivalent of water is removed and a cyclization occurs, followed by a treatment with ethanol and isopropanol.Type: GrantFiled: August 26, 2019Date of Patent: November 16, 2021Assignees: Lonza Guangzhou Pharmaceutical Ltd., Lonza LtdInventors: Jieping Wei, Yanling Yang, Daniel Shan, Reta Zhu, Paul Hanselmann, Dieter Scherer
-
Patent number: 11168117Abstract: The invention relates to an isolated nucleic acid sequence comprising a promoter, which is a native sequence of Pichia pastoris comprising the nucleic acid sequence of pCS1 of SEQ ID 1, or a functionally active variant thereof which is a size variant, a mutant or hybrid of SEQ ID 1, or a combination thereof, expression constructs and recombinant host cells comprising the promoter, and a method of producing a protein of interest under the control of the promoter. It further relates to a method to identify a constitutive promoter from eukaryotic cells, and an isolated nucleic acid sequence comprising a promoter which when operatively linked to a nucleotide sequence encoding a protein of interest directs the expression thereof in a host cell at an expression level that is higher than under control of the native pGAP promoter at high and low growth rates.Type: GrantFiled: July 16, 2019Date of Patent: November 9, 2021Assignee: LONZA LTDInventors: Diethard Mattanovich, Brigitte Gasser, Roland Prielhofer
-
Patent number: 11034721Abstract: Disclosed are methods and devices for the optimization of virus removal from solutions. A method of filtering a process fluid comprising a product includes allowing some of the process fluid to flow from a first reservoir to a viral filter; adding a chase fluid to the process fluid in the first reservoir to form a composite fluid; and allowing the composite fluid to flow from the first reservoir to the viral filter to produce eluent. In some embodiments, flow of fluid across the viral filter is sufficient to avoid significant impairment to viral removal until a preselected event, occurs. In some embodiments, flow of fluid from the first reservoir across the viral filter is maintained in the absence of an interruption or slowing of flow of duration or magnitude sufficient to impair viral removal to a level below a log-reduction value of the viral filter.Type: GrantFiled: December 8, 2017Date of Patent: June 15, 2021Assignee: LONZA LTDInventors: Paul Pease, Wilburn Miller, Jesse Cobb, Anthony Castagnaro, Andrew Harris
-
Patent number: 11008540Abstract: A manufacturing facility for the continuous production of biopharmaceuticals integrated with single-use disposable technology.Type: GrantFiled: October 26, 2016Date of Patent: May 18, 2021Assignee: Lonza Ltd.Inventor: Atul Mohindra